Budesonide high-volume saline irrigations (HVSIs) are routinely used to treat chronic rhinosinusitis (CRS) due to improved sinonasal delivery and efficacy compared to intranasal corticosteroid sprays. The off-label use of budesonide is assumed to be safe, with several studies suggesting the systemically absorbed dose of budesonide HVSI is low. However, the actual budesonide dose retained in the sinonasal cavity following HVSI is unknown. The objective of this study was to quantify the retained dose of budesonide after HVSI.
Methods
Adult patients diagnosed with CRS who had undergone endoscopic sinus surgery (ESS) and were prescribed budesonide HVSI were enrolled into a prospective, observational cohort study. Patients performed budesonide HVSI (0.5 mg dose) under supervision in an outpatient clinic, and irrigation effluent was collected. High-performance liquid chromatography was employed to determine the dose of budesonide retained after HVSI.
Results
Twenty-four patients met inclusion criteria. The average corrected retained dose of budesonide across the cohort was 0.171 ± 0.087 mg (37.9% of administered budesonide). Increased time from ESS significantly impacted the measured retained dose, with those 3 months post-ESS retaining 27.4% of administered budesonide (P = .0004).
Conclusion
The retained dose of budesonide in patients with CRS after HVSI was found to be significantly higher than previously estimated and decreased with time post-ESS. Given that budesonide HVSI is a cornerstone of care in CRS, defining the retained dose and the potential systemic implications is critical to understanding the safety of budesonide HVSI.
OrlandiRRKingdomTTSmithTL, et al.International consensus statement on allergy and rhinology: Rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213–739. DOI: https://doi.org/10.1002/alr.22741
2.
PoetkerDM. Oral corticosteroids in the management of chronic rhinosinusitis with and without nasal polyps: Risks and benefits. Am J Rhinol Allergy. 2015;29(5):339–342. DOI: https://doi.org/10.2500/ajra.2015.29.4223
3.
RudmikLHoyMSchlosserRJ, et al.Topical therapies in the management of chronic rhinosinusitis: An evidence-based review with recommendations. Int Forum Allergy Rhinol. 2013;3(4):281–298. DOI: https://doi.org/10.1002/alr.21096
4.
SnidvongsKKalishLSacksR, et al.Sinus surgery and delivery method influence the effectiveness of topical corticosteroids for chronic rhinosinusitis: Systematic review and meta-analysis. Am J Rhinol Allergy. 2013;27(3):221–233. DOI: https://doi.org/10.2500/ajra.2013.27.3880
5.
HarveyRJSnidvongsKKalishLH, et al.Corticosteroid nasal irrigations are more effective than simple sprays in a randomized double-blinded placebo-controlled trial for chronic rhinosinusitis after sinus surgery. Int Forum Allergy Rhinol. 2018;8(4):461–470. DOI: https://doi.org/10.1002/alr.22093
6.
WelchKCThalerERDoghramjiLL, et al.The effects of serum and urinary cortisol levels of topical intranasal irrigations with budesonide added to saline in patients with recurrent polyposis after endoscopic sinus surgery. Am J Rhinol Allergy. 2010;24(1):26–28. DOI: https://doi.org/10.2500/ajra.2010.24.3418
7.
BhallaRKPaytonKWrightED. Safety of budesonide in saline sinonasal irrigations in the management of chronic rhinosinusitis with polyposis: Lack of significant adrenal suppression. J Otolaryngol Head Neck Surg. 2008;37(6):821–825.
8.
RotenbergBWZhangIArraI, et al.Postoperative care for Samter’s triad patients undergoing endoscopic sinus surgery: A double-blinded, randomized controlled trial. Laryngoscope.2011;121(12):2702–2705. DOI: https://doi.org/10.1002/lary.22396
9.
SmithKAFrenchGMechorB, et al.Safety of long-term high-volume sinonasal budesonide irrigations for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2016;6(3):228–232. DOI: https://doi.org/10.1002/alr.21700
10.
SoudryEWangJVaezeafsharR, et al.Safety analysis of long-term budesonide nasal irrigations in patients with chronic rhinosinusitis post endoscopic sinus surgery. Int Forum Allergy Rhinol. 2016;6(6):568–572. DOI: https://doi.org/10.1002/alr.21724
11.
KhuranaNPulsipherAJedrzkiewiczJ, et al.Inflammation-driven vascular dysregulation in chronic rhinosinusitis. Int Forum Allergy Rhinol. 2021;11(6):976–983. DOI: https://doi.org/10.1002/alr.22723
12.
KhuranaNYathavanBJedrzkiewiczJ, et al.Vascular permeability in chronic rhinosinusitis enhances accumulation and retention of nanoscale pegylated liposomes. Nanomedicine. 2021;38:102453. DOI: https://doi.org/10.1016/j.nano.2021.102453
13.
YathavanBEllisAJedrzkiewiczJ, et al.Systemic administration of budesonide in pegylated liposomes for improved efficacy in chronic rhinosinusitis. J Control Release. 2023;360:274–284. DOI: https://doi.org/10.1016/j.jconrel.2023.06.030
14.
WiseSKDamaskCRolandLT, et al.International consensus statement on allergy and rhinology: Allergic rhinitis - 2023. Int Forum Allergy Rhinol. 2023;13(4):293–859. DOI: https://doi.org/10.1002/alr.23090
15.
RosenfeldRMPiccirilloJFChandrasekharSS, et al.Clinical practice guideline (update): Adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(2_suppl):S1–S39. DOI: https://doi.org/10.1177/0194599815572097
16.
FokkensWJLundVJHopkinsC, et al.European Position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58:1–464. DOI: https://doi.org/10.4193/Rhin20.600
17.
LundVJMackayIS. Staging in rhinosinusitus. Rhinology. 1993;31:183–184.
ShipmanPYBPulsipherASmithKA, et al.Quantification of budesonide retained in the sinonasal cavity after high-volume saline irrigation in post-operative chronic rhinosinusitis and healthy subjects. In: Poster session presented at: Burrell College of Osteopathic Medicine Medical Student Research Day, Las Cruces, NM, 2023 August 12 2023.
22.
HarveyRJDebnathNSrubiskiA, et al.Fluid residuals and drug exposure in nasal irrigation. Otolaryngol Head Neck Surg. 2009;141(6):757–761. DOI: https://doi.org/10.1016/j.otohns.2009.09.006
23.
HarveyRJSnidvongsKKalishLH, et al.Corticosteroid nasal irrigations are more effective than simple sprays in a randomized double-blinded placebo-controlled trial for chronic rhinosinusitis after sinus surgery. Int Forum Allergy Rhinol. 2018;8(4):461–470. DOI: https://doi.org/10.1002/alr.22093
24.
SnidvongsKPrattEChinD, et al.Corticosteroid nasal irrigations after endoscopic sinus surgery in the management of chronic rhinosinusitis. Int Forum Allergy Rhinol. 2012;2(5):415–421. DOI: https://doi.org/10.1002/alr.21047
25.
JangDWLachanasVASegelJ, et al.Budesonide nasal irrigations in the postoperative management of chronic rhinosinusitis. Int Forum Allergy Rhinol. 2013;3(9):708–711. DOI: https://doi.org/10.1002/alr.21189
26.
AbadieWMMcMainsKCWeitzelEK. Irrigation penetration of nasal delivery systems: A cadaver study. Int Forum Allergy Rhinol. 2011;1(1):46–49. DOI: https://doi.org/10.1002/alr.20002
27.
HarveyRJGoddardJCWiseSK, et al.Effects of endoscopic sinus surgery and delivery device on cadaver sinus irrigation. Otolaryngol Head Neck Surg. 2008;139(1):137–142. DOI: https://doi.org/10.1016/j.otohns.2008.04.020
SeiberlingKAChangDFNyiradyJ, et al.Effect of intranasal budesonide irrigations on intraocular pressure. Int Forum Allergy Rhinol. 2013;3(9):704–707. DOI: https://doi.org/10.1002/alr.21180
30.
SilvaB. Incidence of hypocorticolism with long-term use of budesonide irrigations for chronic rhinosinusitis. In American Rhinologic Society @ COSM, Boston, MA, 2023.
Macias-ValleLPsaltisAJ. A scholarly review of the safety and efficacy of intranasal corticosteroids preparations in the treatment of chronic rhinosinusitis. Ear Nose Throat J. 2021;100(5):295–301. DOI: https://doi.org/10.1177/0145561320967727
YellepeddiVKBattagliaMDaviesSJC, et al.Pharmacokinetics of intranasal amiloride in healthy volunteers. Clin Transl Sci. 2023. DOI: https://doi.org/10.1111/cts.13514
35.
AzzehMBattagliaMDaviesS, et al.Novel intranasal treatment for anxiety disorders using amiloride, an acid-sensing ion channel antagonist: Pharmacokinetic modeling and simulation. Int J Clin Pharmacol Ther. 2022;60(6):253–263. DOI: https://doi.org/10.5414/CP204217
36.
YellepeddiVKParasharKDeanSM, et al.Predicting resolving D1 pharmacokinetics in humans with physiologically-based pharmacokinetic modeling. Clin Transl Sci. 2021;14(2):683–691. DOI: https://doi.org/10.1111/cts.12930
37.
KumarNNGautamMLochheadJJ, et al.Relative vascular permeability and vascularity across different regions of the rat nasal mucosa: Implications for nasal physiology and drug delivery. Sci Rep. 2016;6(1):31732. DOI: https://doi.org/10.1038/srep31732
38.
ProtopapaCSiamidiAPavlouP, et al.Excipients used for modified nasal drug delivery: a mini-review of the recent advances. Materials (Basel). 2022;15(19):6547. https://doi.org/10.3390/ma15196547
39.
YathavanBEllisAJedrzkiewiczJ, et al.Systemic administration of budesonide in pegylated liposomes for improved efficacy in chronic rhinosinusitis. J Control Release2023;360:274–284.
